Sotirimod

Overview

Sotirimod (R850) is a TLR7 agonist and immunomodulator. Sotirimod inhibits Apoptosis . Sotirimod is applicable to research related to actinic keratosis, early cervical HPV infection , and precancerous lesions of colorectal cancer .

Application

Products | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > HPV-Positive Cervical Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-101589
• CAS No.: 227318-75-4
• Molecular Formula: C14H17N5
• Molecular Weight: 255.32
• Purity: 99.90%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
• Availability: In-stock

Source

Original product source